NCT02099058
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 99 Years (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Subject has known uncontrolled metastases to the central nervous system (CNS)
https://ClinicalTrials.gov/show/NCT02099058